参考文献
[1]张斌，蔡玉娥，张齐，等.新辅助化疗用于可手术乳腺瘤的10年疗效[J].中国肿瘤临床，2002，29(3)：157-159.
[2]Murata y，Ogawa Y.Yoshida S.et al.Utility of initial MRI for predicting extent of residual disease after neoadjuvant chernotherapy：ana)ysis of 70 breast cancer patients[J].Onco1 Rep.2004，12(6)：1257-1262.
[3]Kang S H，Kim S K，Kwon Y，et al.Decreased identification rate of sentinel lymphnode after neoadjuvant chemotherapy[J].World J Surg.2～4，28(10)：1019-1024.
[4]Xing Y，Cormier J N，Kuerer H M.et al.Sentinel lymph node biopsy following neoadjuvant chernotherapy：revlew of the Iiterature and recornmendations for use in patient management[J].Asian J Surg，2004，27(4)：262-267.
[5]黄信孚，林本耀主编.现代肿瘤学诊疗手册[M].北京：北京医科大学中国协和医科大学联合出版社，1995：484-486.
[6]Bui，Kimmie L.Lamb.et al.Accuracy of mammographic and sonographic assessment of preoperative breast cancer[J].Size.Women's lmuging.2003，5(3)：128.
[7]Inaji H.Komoike Y.Motomura K，et al.Breast-con serving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breust Ca ncer，2002，9(1)：20.
[8]骆成玉.乳腺疾病的微创与功能治疗[J].实用临床医药杂志，2003，7(5)：425-429.
[9]骆成玉，张键.林华，等.乳腺癌新辅助化疗的临床评价和时机选择[J].乳腺病杂志，2004，2(4)：35-37.
[10]Fisher B，Bryant J，Wolmark N，et al.Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer[J].J Clin Onco1，1998，16，2572-2685.
[11]Marshall J，Chen H，Yang D，et al.A phase 1 trial of a Bcl2 antisense(G3139)and weekly docetaxel in patients with advanced breast cancer and other solid tumors[J].Ann Oncol，2004，15(8)：1274-1283.
[12]Kuerer H M，Newman L A，Buzder A U，et al.Residual metastatic axillary 1ymph nodes following neoadjuvant chcmotherapy predict disease free survival in patients with locally advanced breast cancer[J].Am J Surg，1998，176：502-509.
[13]Hutcheon A W，Heys S D，Millcr I D，et al.Improvement in survival in patients receiving primary chemotherapy with docetaxel for breast cancer：a randomized controlled trial[J].Breast Cancer Res Treat，2001，69(3)：298.
[14]DeMaria M，Volm K，Skinner，et al.Five?year outcome of locally advanced cancer(LABC)patients after neo?adjuvant concurrent 5 fluorouracil and radiation(FU/RT)[J].Proceedings of ASCO，2002，21(31b)：1934.
[15]Adjei A A，Dy G K，Erlichman C，et al.A phase 1 trial of 1-SIS 2503，an antisense inhibitor of H-ras，in combination with gemcitabine in patients with advanced cancer[J].Clin Cuncer Res，2003，9(1)：115-123.
[16]Cance W G，Carey L A，Calvo B F.et al.Long-term outcome of neoadjuvant therapy for 10cally advanced breast carcinoma：effcctive clinical downstaging allows breast preservation and predicts outstanding local control and survival[J].Ann Surg，2002，236(3)：295-302.
[17]Saleh M N，Sugarman S，Murray J，et al.Phase 1 trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors[J].J Clin Oncol，2000，18(11)：2282-2292.
[18]Green M，Hortobagyi G N.Neoadjuvant chemotherapy for operab1e breast cancer[J].Oncology，2002，16(7)：871-884.889.
[19]Dixon J M，Jackson J，Renshaw L，et al.Neoadjuvant tamoxifen and aromatase inhibitors：comparisons and clinical outcomes[J].J Steroid Biochem Mol Biol，2003，86(3-5)：295-299.
[20]Tolcher A W，Sugarman S，Gelmon K A，et al.Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer[J].J Clin Oncol，1999，17(2)：478-484.
[21]Eltarur A，Heys S D，Hutcheon A W，et al.Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy[J].Am J Surg，1998，175(2)：127-132.
[22]Dillman R O.Monoclonal antibodies in the treatment of malignancy：basic concepts and recent developments[J].Cu ncer lnvest，2001，19(8)：833-841.
[23]Patel N A，Piper G，Patel J A，et al.Accu axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer[J].Am Surg，2004，70(8)：696-699.
[24]Buchholz T A，Hunt K K，Whltrnan G J，et al.Neoadjuvant chemotherapy for breast carcinoma：multidisciplinary considerations of benefits and risks[J].Cancer，2003，98(6)：1150-1160.(https://www.daowen.com)
[25]Ranson M，Sliwkowski M X.Perspectives on anti-HER monoclonal antibodies[J].Oncology，2002，63 Suppl 1：17-24.
[26]Earl H.American Society for Clinical Oncology.American Society for Clinical Oncology 39th Annual Meeting，Chicago，lllinois，USA，31 May to 3 Junc 2003：breast.
[27]Dixon J M，Anderson T J，Miller W R.Neoadjuvant endocrine therapy of breast cancer；a surgical perspective[J].Eur J Cancer，2002，38(17)：2214-2221.
[28]Andcrson T J，Dixon J M，Stuart M.et al.Effect of neoadjuvant treatment with anastrozole on tumour histology in postmeno-Prospecpausal women with large operable breast cancer[J].Br J Cancer，2002，87(3)：334-338.
[29]Wenzel C，Bartsch R，Locker G J，et al.Preoperative chemotherapy with epidoxorubicin，docetaxel and capecitabine plus pegfolgrastim in patients with primary breast cancer[J].Anticancer Drugs，2005：16.441-445.
[30]Posey J A，et al.A phase 1 study of anti-kinase insert domain-containing receptor antibody，IMC-ICll，in patients with liver metastases from colorectal carcinoma[J].Clin Cancer Res，2003，9(4)：1323-1332.
[31]Duff S E，et al.CDI05 is important for angiogenesis：evidence and potential applications[J].F ASEB J，2003，17(9)：984-992.
[32]Popat S，Smith I E.Re1ated Articles，et al.Neoadjuvant versus adjuvant systemic treatment in breast cancer：a meta-analysis[J].J NatJ Cancer Inst，2005，97(11)：858.
[33]Hannemann J，Oosterkamp H M，Bosch C A，et al.Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer[J].J Clin Oncol，2～5；23(1 5)：3331-3342.
[34]Seidman A，Hudis C，Pierri M K，et al.Cardiac dysfunction in the trastuzumab clinical trials experience[J].J Clin Oncol，2002，20(5)：1215-211.
[35]Smith I E，Walsh G，Jones A，et al.High comp1ete remlsslon rate wilh pnmary neoadjuvant infusional chcmotherapy for large ear1y breast canncer[J].J Clin Oncol，1995，13：424-429.
[36]Pickles M D，Lowry M，et al.Role of dy namic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy[J].Breast Cancer Res Treat，2005，91(1)：1-10.
[37]Mamounas E P.Sentinel lymph node biopsy afler neoadjuvant systcrnic thcrapy[J].Surg Clin N Am，2003，83：931-942.
[38]Patel N A，Piper G，PateJ J A.et al.Accu-Usrate axillary noda1 staging can be achieved after neoadjuvant therapy for locally advanced breast cancer[J].Am Surg，2004，70：696-699.
[39]Rouzier R，Mathieu M-C，Sideris L，et al.Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors[J].Cancer，2004，101：918-925.
[40]Puglisi F，Mansutti M，Aprile G，et al.Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophasphamide followed by docetaxe1 in patients with breast cancer[J].Anticancer Res，2004，24：2487-2493.
[41]Favret A M，Carlson R W，Goffinet D R，et al.Locally advanced breast cancer.Is surgery necessary?[J]The Breast Journa1，2001，7：131-137.
[42]Yeh E，Slanetz，Kopans D B，et al.Prospec tlve compa nson of mamrnography，sonography，and MRI in patienls undergoing neoadjuvant chemotherapy for palpable breast cancer[J].AJR Am J Roentgenol，2005，184：868-877.
[43]Freedman O C，Verma S，Clemons M J.Using aromatasc inhibitors in the neoadjuvant setting：evolution or revolution?[J]Cancer Treat Rev，2005，31：1-17.
[44]Rouzier R，Mathieu M C，Sideris L，et al.Breast-conserving surgery afler neoaùjuvanl anthracycline-based chemotherapy for 1arge breast tumors[J].Cancer，2004，1，101(5)：918-925.
[45]Espinosa E，Morales S，Borrega P，et al.Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in 1ocally advanced breast cancer[J].Cancer Chcmother Pharmacol，2004，54(6)：546-552.
[46]Ayers M，Syrrunans W F，Stec J，et al.Gene expression promcs predict COInpictc pathologic response to neoadjuvant paclitaxel and fluorouracil，doxorubicin.and cyclophosphamide chernotherapy in breast cancer[J].J Clin Oncol，2004，22(12)：2284-2293.
[47]Ru R T，Schott A F，Slurtz D E，et al.Pathologic featurcs of breast cancer associated with complete response to neoadjuvant chemotherapy：importance of tumor neorosis[J].Am J Surg Pathol，2005，29：354-358.
[48]Cleator S J，Makris A，Ashley S E，et al.Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associatecl with improved overall survial[J].Ann Oncol，2005，16：267-272.